Skip to main content

Licensing Opportunities available from Warwick Ventures

biology logo Chemistry logo Computing logo Engineering logo Medicine logo Physics logo
Biology Chemistry Computing Engineering Medicine Physics

These pages contain details of the technologies currently available to licence from Warwick Ventures.
If you would like more details of any of these technologies, please contact the relevant Business Development
Manager.

New technologies are added regularly, so do please register your interest and we will send through details of
opportunities as they are published. You can also use the RSS feed on the Licensing Opportunities page to
keep up to date.


Improvements to electrospray ionisation

A University of Warwick team, led by Professor Pete O’Connor, has available for licence intellectual property using CI to increase the average charge state of ions generated by electrospray ionisation.

More details: Improvements to eletrospray ionisation

Contact: Dr Shum Prakash, Business Development Manager, Warwick Ventures. Tel: +44 (0) 24 7657 4145; email:s.prakash@warwick.ac.uk

Tue 04 October 2016, 13:23 | Tags: Chemistry

Two-dimensional mass spectrometry in any inexpensive linear ion trap

A University of Warwick team, led by Professor Pete O’Connor, has available for licence intellectual property relating to a method of two dimensional mass spectrometry, to be utilised in any mass spectrometer containing a linear ion trap.

More details: Two-dimensional mass spectrometry in any inexpensive linear ion trap

Contact: Dr Shum Prakash, Business Development Manager, Warwick Ventures. Tel: +44 (0) 24 7657 4145; email:s.prakash@warwick.ac.uk

Tue 04 October 2016, 12:51 | Tags: Chemistry

Improved Hip Prostheses

image

Warwick Ventures has available for licence a patent application covering a truly ground breaking innovation in the design of hip prostheses which enables the reduction of “edge-loading” stresses responsible for the degradation of the devices over time.

More details: Improved hip prostheses

Contact: Laura Lane, Business Development Manager, Warwick Ventures. Tel: (0)24 765 75745
Email: l.lane@warwick.ac.uk

Tue 09 February 2016, 14:09 | Tags: Life Sciences and Biotechnology

IVF pre-implantation screening method

image

A team at the University of Warwick has developed a new screening test that potentially provides an accurate and noninvasive method for assessing embryos during IVF treatment, prior to implantation.

More details: IVF pre-implantation screening method

Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk

Thu 17 December 2015, 11:38 | Tags: Life Sciences and Biotechnology

Increased Epigenetic Variation in Plants

image

A team at the University of Warwick has developed technology to increase the epigenetic variety of plants without the usual undesired side effects. The novel strategy allows a much greater range of epigenetic and phenotypic differences to be introduced than was previously possible.

More details: Increased epigenetic variation in plants

Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk

Mon 23 November 2015, 16:02 | Tags: Life Sciences and Biotechnology

New Test to Accurately Determine the Onset of Labour

image

A team at the University of Warwick has developed a new test that provides an accurate way to confirm the onset of labour in both full term and preterm pregnancies. A second application for the test is expected to be the identification of women who may not progress during induction.

More details: A new test to accurately determine the onset of labour

Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk

Mon 23 November 2015, 15:01 | Tags: Medicine and Pharmaceuticals

Novel, highly stable, Os(II) arene/TsDPEN complexes for asymmetric hydrogenation of prochiral substrates

Warwick Ventures has available for licence a novel series of catalytically-active Os(II) complexes described by Professors Peter Sadler and Martin Wills and their team at the University of Warwick, UK. Advantages include the
high stability of the catalysts, which are readily synthesised in under an hour and may be stored for several months before use, without loss of activity.

More details: Novel Osmium Catalysts

Contact: Dr Shum Prakash, Business Development Manager, Warwick Ventures. Tel: +44 (0) 24 7657 4145; email: s.prakash@warwick.ac.uk

Mon 07 September 2015, 11:55 | Tags: Chemistry

Novel characteristics to identify appropriate electron acceptors for organic photovoltaics

Warwick Ventures has available for licence a proven design rule, developed by Professor Alessandro Troisi, for the construction of a large family of electron acceptor materials that can replace fullerene derivatives in organic photovoltaic devices. The rule will enable the development of cost-effective and more efficient organic solar cells.

More details: Novel characteristics to identify appropriate electron acceptors for organic photovoltaics

Contact: Dr Shum Prakash, Business Development Manager, Warwick Ventures. Tel: +44 (0) 24 7657 4145; email: s.prakash@warwick.ac.uk

Mon 03 November 2014, 11:52 | Tags: Chemistry

Novel Tethered Ru(II) arene/TsDPEN complexes using a novel and concise ‘arene swapping’ method

image

Warwick Ventures has available for licence a new method for the formation of Ru(II) complexes. This method, in which a [Ru(arene)Cl2]2 complex is converted directly to a tethered Ru(II) complex in one step, was developed by Professor Martin Wills and his team at the University of Warwick, UK. Advantages include the synthesis of new catalysts and a concise route with no need for the use of a cyclohexadiene intermediate or a Birch-reduction step.

More details: Novel Tethered Ru(II) arene/TsDPEN complexes using a novel and concise ‘arene swapping’ method

Contact: Dr Shum Prakash, Business Development Manager, Warwick Ventures. Tel: (0)24 7657 4145; email: s.prakash@warwick.ac.uk

Fri 05 September 2014, 14:14 | Tags: Chemistry

A novel target and therapeutic leads for the treatment of bovine and human RSV

image

Warwick Ventures has available for licence a patent application covering an entirely novel conserved host cell protein target for the treatment of bovine and human RSV. Promising proof-of-concept studies have demonstrated significant anti-viral activity with a number of chemical lead compounds which are suitable for entry into a drug discovery program.

More details: A novel target and therapeutic leads for the treatment of bovine and human RSV

Contact: Andrew Lee, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75745; email: L.Lane@warwick.ac.uk

Tue 22 July 2014, 15:39 | Tags: Life Sciences and Biotechnology

Older news